In 2015, Inovio Pharmaceuticals started a Phase I trial of INO-5150 — a new type of immunotherapy using a DNA vaccine for prostate cancer which targets both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: biochemical, DNA, INO-5150, recurrence, Treatment, vaccine | Leave a comment »
According to a media report on the MarketWatch web site, a company called OncBioMune is to initiate Phase II clinical trials of a new type of prostate cancer vaccine (ProscaVax). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cancer, localized, Phase II, prostate, trial, vaccine | 2 Comments »
A company called OncBioMune Pharmaceuticals has announced initial data from a Phase Ia/Ib clinical trial of a new form of vaccine in the treatment of men with progressive prostate cancer who meet the following criteria: … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: OncBioMune, trial, vaccine | 2 Comments »
A study just published in European Urology has suggested that early therapy with Prostvac-type vaccines might have value in the management of men with a rising PSA after first-line therapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: progressive, Prostvac, PSA, rising, vaccine | 2 Comments »
A new article on the Medscape Oncology web site (and again correlated with a media release sent out by the European Association for Urology [EAU] from their annual meeting in Milan, Italy) is headed “Prostate cancer vaccine shows promise.” However, the degree of that “promise” appears to be open to some question. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: castration, dexamethasone, multi-peptide, outcome, PSA, resistant, trial, vaccine | 7 Comments »
A research team at the University of Iowa is seeking patients to enroll in Phase II clinical trials of a new form of vaccine immunotherapeutic to treat men with recurrent prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: adenovirus, castration-resistant, recurrent, trial, vaccine | 8 Comments »
The idea that we might be able to use a single therapeutic “vaccine” to treat patients with many different types of cancer is not new … and has yet to be substantiated in any large clinical trial. However, … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: ImMucin, therapeutic, vaccine | 2 Comments »
In May this year we initially commented on a media announcement about a new form of vaccine-like therapy that was entering Phase III clinical trials for the first-line treatment of intermediate- and high-risk prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: ProstAtak, radiation, Theragene, vaccine | 2 Comments »
Now curing prostate cancer in mice absolutely does not necessarily imply that the same vaccine can be used to “cure prostate cancer in man,” … but the technical capability is certainly a step in the right direction (if it really is true). … READ MORE …
Filed under: Drugs in development | Tagged: cure, mouse, vaccine | 5 Comments »
A biopharmaceutical company called Advantagene, Inc. announced last Thursday that it has reached agreement with the U.S. Food and Drug Administration regarding the conduct of a Phase III clinical trial of a vaccine-like treatment called ProstAtak™ — in combination with standard therapy — in the treatment of patients with newly diagnosed prostate cancer. … READ MORE …
Filed under: Drugs in development, Management | Tagged: AdV-tk, gene suicide, immunotherapy, localized, ProstAtak, vaccine, valacyclovir | Leave a comment »
As some readers may be aware, one of the great biologic discoveries of the late 20th Century was the association between the length of the telomere (a piece of repeating DNA at the tips of each chromosome) and the ability of an individual cell to divide and replicate. … READ MORE …
Filed under: Drugs in development | Tagged: Adamis, TeloB-VAX, telomerase, telomere, vaccine | Leave a comment »
Research into new “vaccine” immunotherapies for prostate cancer continues to be a hot topic following the approval of Dendreon’s Provenge just 3 weeks ago. … READ MORE …
Filed under: Drugs in development | Tagged: AE37, immunotherapy, vaccine | Leave a comment »
Straight from a “late-breaking poster” at the annual meeting of the Association for the Advancement of Cancer Research going on in Washington, DC, comes data about BPX-101 — another dendritic cell-based immunotherapeutic “vaccine” for the possible treatment of late-stage prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: BPX-103, castration-resistant prostate cancer, CRPC, vaccine | 3 Comments »
We have heard that another investigational vaccine therapy has started Phase I clinical trials that will include patients with advanced prostate cancer who “have failed at least 1 course of an accepted hormonal therapy.” … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: DPX-0907, trial, vaccine | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 